July 7, 2020 – Medtronic announced it received U.S. Food and Drug Administration (FDA) clearance and European CE mark approval for its Linq II insertable cardiac monitor (ICM) with remote programming, which enables clinicians to optimize device settings without the need for patients to return to the office or hospital.

Canon Medical Systems USA has created a virtual trade-show experience for its cardiovascular computed tomography (CT) offerings at the 2020 Society of Cardiovascular Computed Tomography (SCCT) virtual meeting July 16-19. With CT positioned as a first-line diagnostic tool addressing the evolving needs of cardiac imaging, hospitals have the ability to deliver high quality, consistent CT studies that are critical to outcomes. 

July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major adverse outcomes, including death, compared to white patients.

Step 2/3

Drug-Coated Balloons

Drug-coated balloons (DCB), also referred to as drug-eluting balloons, are used to treat peripheral and coronary artery lesions and restenosis. The balloons carry an antiproliferative drug that is delivered to the wall of arteries when the balloon is expanded. The drug helps prevent neointimal hyperplasia caused by vessel trauma from the balloon angioplasty. Find news and video content on DCBs

Chart File
Drug eluting balloons chart WEB V1 2020.csv10.68 KB
Three of the most popular cardiovascular technologies to make news in June 2020. Top is the Impella Expandable Cardiac Pump (ECP) that is about to enter U.S. feasibility trials.Bottom left, the Foldax heart valve uses a flexible man-made material for valve leaflets rather than animal pericardium tissue. The hope is this new type of surgical and transcatheter aortic valve replacements (TAVR) device will enhance longevity of the valve leaflets. Bottom right, the SMT Hydra TAVR valve is the first Indian-made s

July 6, 2020 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) magazine website from the month of June 2020. This is based on the website’s 267,198 pageviews for the month. While COVID-19 topics still are among the popular topics on the list, there has been a noticable return to normal reader interest in new cardiovascular technologies.
 

July 1, 2020 — Carag AG announced receiving U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) approval for its Carag Bioresorbable Septal Occluder (CBSO). The CE-marked CBSO is the first-ever transcatheter septal occluder with bioresorbable, metal-free framework. Carag's first U.S. trial is designed to enroll up to 250 patients in a staged study approach, the largest clinical trial for the company to date.

Thoracic findings in a 15-year-old girl with Multisystem Inflammatory Syndrome in Children (MIS-C). (a) Chest radiograph on admission shows mild perihilar bronchial wall cuffing. (b) Chest radiograph on the third day of admission demonstrates extensive airspace opacification with a mid and lower zone predominance. (c, d) Contrast-enhanced axial CT chest of the thorax at day 3 shows areas of ground-glass opacification (GGO) and dense airspace consolidation with air bronchograms. (c) This conformed to a mosai

In recent weeks, a multisystem hyperinflammatory condition has emerged in children in association with prior exposure or infection to SARS-CoV-2. A new case series published in the journal Radiology examines the spectrum of imaging findings in children with the post-COVID-19 inflammatory condition known in the U.S.

June 30, 2020 — DiA Imaging Analysis, a leading provider of advanced AI-based solutions for ultrasound analysis, announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) 510(k) and a European CE mark for two additional AI-powered ultrasound analysis solutions.

June 30, 2020 — A new study shows that SARS-CoV-2, the virus that causes COVID-19 (coronavirus), can infect heart cells in a lab dish, indicating it may be possible for heart cells in COVID-19 patients to be directly infected by the virus.

June 30, 2020 —  BioCardia, Inc. announced that the company has resumed cases in the CardiAMP Heart Failure Trial. The first patient procedure completed since elective procedures were paused due to COVID-19 took place at Morton Plant Hospital in Clearwater, Florida this month. New consents have also taken place at additional centers. 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now